Objectives: Favorable phase I results justified this pilot phase II study to assess the efficacy of docetaxel/curcumin in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (CRPC). Methods: Thirty patients with progressing CRPC and a rising prostate-specific antigen (PSA) received docetaxel/prednisone in standard conditions for 6 cycles in combination with per os curcumin, 6,000 mg/day (day -4 to day +2 of docetaxel). The co-primary endpoint was the overall response rate determined by PSA and target assessments. An ancillary study assessed the seric values of chromogranin A (CgA) and neuron-specific enolase (NSE). Results: Twenty-six patients received the scheduled treatment, 2 progressed and 2 died before the end of treatment. A PSA response was observed in 59% of patients (14% of PSA normalization) and achieved within the first three cycles for 88% of responders. Partial response was reached for 40% of evaluable patients. The regimen was well tolerated, and no adverse event was attributed to curcumin. Twenty patients were 100% curcumin compliant. The PSA level and objective response rate were not correlated with the serum values of CgA and NSE. Conclusion: This study produced additional data on curcumin as a treatment for cancer, with a high response rate, good tolerability and patient acceptability, justifying the interest to conduct a randomized trial.

1.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
2.
Bemis DL, Katz AE, Buttyan R: Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs 2006;15:1191-1200.
3.
Thangapazham RL, Sharma A, Maheshwari RK: Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J 2006;8:E443-E449.
4.
Gupta SC, Patchva S, Aggarwal BB: Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013;15:195-218.
5.
Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB: Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation. Mol Pharmacol 2006;69:195-206.
6.
Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB: Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001;20:7597-7609.
7.
Srivastava RK, Chen Q, Siddiqui I, Sarva K, Shankar S: Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21/WAF1/CIP1. Cell Cycle 2007;6:2953-2961.
8.
Choudhuri T, Pal S, Das T, Sa G: Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 2005;280:20059-20068.
9.
Bae M-K, Kim S-H, Jeong J-W, Lee YM, Kim H-S, Kim S-R, et al: Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 2006;15:1557-1562.
10.
Choi HY, Lim JE, Hong JH: Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells. Prostate Cancer Prostatic Dis 2010;13:343-349.
11.
Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ: Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 2005;280:6301-6308.
12.
Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP: Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer 2005;113:490-498.
13.
Choi BH, Kim CG, Lim Y, Shin SY, Lee YH: Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NFκB pathway. Cancer Lett 2008;259:111-118.
14.
Ide H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, et al: Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 2010;70:1127-1133.
15.
Chen WT-L, Yang T-S, Chen H-C, Chen H-H, Chiang H-C, Lin T-C, et al: Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil-based chemotherapy in colorectal cancer. Nutr Res 2014;34:585-594.
16.
Thomas R, Williams M, Sharma H, Chaudry A, Bellamy P: A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer - the UK NCRN Pomi-T study. Prostate Cancer Prostatic Dis 2014;17:180-186.
17.
Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, et al: A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011;68:157-164.
18.
Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14:4491-4499.
19.
Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, et al: Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 2010;9:8-14.
20.
Vashchenko N, Abrahamsson P-A: Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005;47:147-155.
21.
di Sant'Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992;70:254-268.
22.
Ather MH, Abbas F, Faruqui N, Israr M, Pervez S: Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol 2008;8:21.
23.
Ferrero-Poüs M, Hersant AM, Pecking A, Brésard-Leroy M, Pichon MF: Serum chromogranin-A in advanced prostate cancer. BJU Int 2001;88:790-796.
24.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-1159.
25.
Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
26.
Galsky MD, Vogelzang NJ: Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 2010;21:2135-2144.
27.
Eymard J-C, Priou F, Zannetti A, Ravaud A, Lepillé D, Kerbrat P, et al: Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 2007;18:1064-1070.
28.
Caffo O, Sava T, Comploj E, Fariello A, Zustovich F, Segati R, et al: Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int 2008;102:1080-1085.
29.
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-2900.
30.
Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al: Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006;6:10.
31.
Fléchon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, et al: Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011;22:2476-2481.
32.
Loriot Y, Massard C, Gross-Goupil M, Palma MD, Escudier B, Bossi A, et al: Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009;20:703-708.
33.
Steineck G, Reuter V, Kelly WK, Frank R, Schwartz L, Scher HI: Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol Stockh Swed 2002;41:668-674.
34.
Cabrespine A, Guy L, Gachon F, Curé H, Chollet P, Bay J-O: Circulating chromogranin A and hormone refractory prostate cancer chemotherapy. J Urol 2006;175:1347-1352.
35.
Cabrespine-Faugeras A, Bayet-Robert M, Bay J-O, Chollet P, Barthomeuf C: Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment. Nutr Cancer 2010;62:148-153.
36.
Zissimopoulos A, Bantis A, Sountoulides P, Giannakopoulos S, Kalaitzis C, Agelonidou E, et al: The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state. Hell J Nucl Med 2009;12:234-237.
37.
Bonkhoff H, Stein U, Remberger K: Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994;25:42-46.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.